Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial.

Miki K, Maekura R, Nagaya N, Nakazato M, Kimura H, Murakami S, Ohnishi S, Hiraga T, Miki M, Kitada S, Yoshimura K, Tateishi Y, Arimura Y, Matsumoto N, Yoshikawa M, Yamahara K, Kangawa K.

PLoS One. 2012;7(5):e35708. doi: 10.1371/journal.pone.0035708. Epub 2012 May 1.

PMID:
22563468
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effects of ghrelin treatment on exercise capacity in underweight COPD patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment.

Miki K, Maekura R, Nagaya N, Kitada S, Miki M, Yoshimura K, Tateishi Y, Motone M, Hiraga T, Mori M, Kangawa K.

BMC Pulm Med. 2013 Jun 10;13:37. doi: 10.1186/1471-2466-13-37.

PMID:
23758800
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.

Ambrosino N, Foglio K, Balzano G, Paggiaro PL, Lessi P, Kesten S; Tiotropium Multicentric Italian Study Group.

Int J Chron Obstruct Pulmon Dis. 2008;3(4):771-80.

PMID:
19281092
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.

Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M.

Drugs. 2008;68(14):1975-2000.

PMID:
18778120
[PubMed - indexed for MEDLINE]
5.

Treatment of cachexia with ghrelin in patients with COPD.

Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, Kangawa K.

Chest. 2005 Sep;128(3):1187-93.

PMID:
16162705
[PubMed - indexed for MEDLINE]
6.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:43-55. doi: 10.2147/COPD.S27319. Epub 2012 Feb 3. Erratum in: Int J Chron Obstruct Pulmon Dis. 2012;7:765.

PMID:
22334768
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators.

COPD. 2012 Apr;9(2):90-101. doi: 10.3109/15412555.2012.661492. Epub 2012 Feb 9.

PMID:
22320148
[PubMed - indexed for MEDLINE]
9.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
[PubMed - indexed for MEDLINE]
10.

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.

Clin Ther. 2007 Feb;29(2):261-78.

PMID:
17472819
[PubMed - indexed for MEDLINE]
11.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
[PubMed - indexed for MEDLINE]
12.

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:57-71. doi: 10.2147/COPD.S27320. Epub 2012 Feb 3.

PMID:
22334769
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:73-86. doi: 10.2147/COPD.S29444. Epub 2012 Feb 3.

PMID:
22334770
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.

Majewski S, Slomka S, Zielinska-Wyderkiewicz E, Ciebiada M, Gorski P.

Am J Cardiovasc Drugs. 2012 Jun 1;12(3):179-88. doi: 10.2165/11597400-000000000-00000.

PMID:
22409211
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.

Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K.

Drugs. 2009 Jun 18;69(9):1205-16. doi: 10.2165/00003495-200969090-00005.

PMID:
19537837
[PubMed - indexed for MEDLINE]
16.

High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.

Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, Loo CK, Chan MH.

Chest. 2013 Jul;144(1):106-18. doi: 10.1378/chest.12-2357.

PMID:
23348146
[PubMed - indexed for MEDLINE]
17.

Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study.

Li JS, Li SY, Yu XQ, Xie Y, Wang MH, Li ZG, Zhang NZ, Shao SJ, Zhang YJ, Zhu L, Guo LX, Bai YP, Wang YF.

J Ethnopharmacol. 2012 Jun 1;141(2):584-91. doi: 10.1016/j.jep.2011.08.060. Epub 2011 Sep 5.

PMID:
21911051
[PubMed - indexed for MEDLINE]
18.

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.

Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, Kesten S, Towse L.

Chest. 2002 Jul;122(1):47-55.

PMID:
12114338
[PubMed - indexed for MEDLINE]
19.

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J.

Lancet. 1998 Mar 14;351(9105):773-80. Erratum in: Lancet 1998 Jun 27;351(9120):1968.

PMID:
9519948
[PubMed - indexed for MEDLINE]
20.

Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.

Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B; INDORSE Study Investigators.

Chest. 2011 Jul;140(1):68-75. doi: 10.1378/chest.10-1830. Epub 2011 Feb 24.

PMID:
21349928
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk